208 related articles for article (PubMed ID: 36436175)
1. Orexin Receptor Antagonists in the Treatment of Depression: A Leading Article Summarising Pre-clinical and Clinical Studies.
Fagan H; Jones E; Baldwin DS
CNS Drugs; 2023 Jan; 37(1):1-12. PubMed ID: 36436175
[TBL] [Abstract][Full Text] [Related]
2. Orexin Receptor Antagonists and Insomnia.
Wu X; Xue T; Chen Z; Wang Z; Chen G
Curr Psychiatry Rep; 2022 Oct; 24(10):509-521. PubMed ID: 35972717
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review.
Shariq AS; Rosenblat JD; Alageel A; Mansur RB; Rong C; Ho RC; Ragguett RM; Pan Z; Brietzke E; McIntyre RS
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():1-7. PubMed ID: 30576764
[TBL] [Abstract][Full Text] [Related]
4. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
5. Orexin OX
Jacobson LH; Chen S; Mir S; Hoyer D
Curr Top Behav Neurosci; 2017; 33():105-136. PubMed ID: 27909987
[TBL] [Abstract][Full Text] [Related]
6. Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
Winrow CJ; Renger JJ
Br J Pharmacol; 2014 Jan; 171(2):283-93. PubMed ID: 23731216
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders.
Muehlan C; Vaillant C; Zenklusen I; Kraehenbuehl S; Dingemanse J
Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1063-1078. PubMed ID: 32901578
[TBL] [Abstract][Full Text] [Related]
8. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.
Han Y; Yuan K; Zheng Y; Lu L
Neurosci Bull; 2020 Apr; 36(4):432-448. PubMed ID: 31782044
[TBL] [Abstract][Full Text] [Related]
9. The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia.
Brooks S; Jacobs GE; de Boer P; Kent JM; Van Nueten L; van Amerongen G; Zuiker R; Kezic I; Luthringer R; van der Ark P; van Gerven JM; Drevets W
J Psychopharmacol; 2019 Feb; 33(2):202-209. PubMed ID: 30644312
[TBL] [Abstract][Full Text] [Related]
10. Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice.
Mahoney CE; Mochizuki T; Scammell TE
Sleep; 2020 Jun; 43(6):. PubMed ID: 31830270
[TBL] [Abstract][Full Text] [Related]
11. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
Roecker AJ; Cox CD; Coleman PJ
J Med Chem; 2016 Jan; 59(2):504-30. PubMed ID: 26317591
[TBL] [Abstract][Full Text] [Related]
12. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.
Sun Y; Tisdale RK; Kilduff TS
Front Neurol Neurosci; 2021; 45():22-37. PubMed ID: 34052813
[TBL] [Abstract][Full Text] [Related]
13. The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders.
Boss C; Gatfield J; Brotschi C; Heidmann B; Sifferlen T; von Raumer M; Schmidt G; Williams JT; Treiber A; Roch C
ChemMedChem; 2020 Dec; 15(23):2286-2305. PubMed ID: 32937014
[TBL] [Abstract][Full Text] [Related]
14. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics.
Janto K; Prichard JR; Pusalavidyasagar S
J Clin Sleep Med; 2018 Aug; 14(8):1399-1408. PubMed ID: 30092886
[TBL] [Abstract][Full Text] [Related]
15. Orexin Receptor Antagonists: Historical Perspectives and Future Opportunities.
Andrews SP; Aves SJ; Christopher JA; Nonoo R
Curr Top Med Chem; 2016; 16(29):3438-3469. PubMed ID: 26416477
[TBL] [Abstract][Full Text] [Related]
16. Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease.
Kron JOJ; Keenan RJ; Hoyer D; Jacobson LH
Annu Rev Pharmacol Toxicol; 2024 Jan; 64():359-386. PubMed ID: 37708433
[TBL] [Abstract][Full Text] [Related]
17. Orexin Receptor Antagonists as Adjunct Drugs for the Treatment of Depression: A Mini Meta-Analysis.
Uğurlu M
Noro Psikiyatr Ars; 2024; 61(1):77-84. PubMed ID: 38496221
[TBL] [Abstract][Full Text] [Related]
18. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?
Khoo SY; Brown RM
CNS Drugs; 2014 Aug; 28(8):713-30. PubMed ID: 24942635
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs.
Kumar A; Chanana P; Choudhary S
Pharmacol Rep; 2016 Apr; 68(2):231-42. PubMed ID: 26922522
[TBL] [Abstract][Full Text] [Related]
20. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.
De Boer P; Drevets WC; Rofael H; van der Ark P; Kent JM; Kezic I; Parapatics S; Dorffner G; van Gerven J; Beneš H; Keicher C; Jahn H; Seiden DJ; Luthringer R
J Psychopharmacol; 2018 Jun; 32(6):668-677. PubMed ID: 29848147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
